Literature DB >> 15059609

A new role in hemostasis for the adhesion receptor P-selectin.

Beatrice Cambien1, Denisa D Wagner.   

Abstract

The adhesion receptor P-selectin has long been known to support leukocyte rolling and emigration at sites of inflammation. Recently, P-selectin was also revealed to be a key molecule in hemostasis and thrombosis, mediating platelet rolling, generating procoagulant microparticles containing active tissue factor and enhancing fibrin deposition. Elevated levels of plasma P-selectin are indicative of thrombotic disorders and predictive of future cardiovascular events. Because the interaction between P-selectin and its receptor P-selectin glycoprotein ligand-1 (PSGL-1) represents an important mechanism by which P-selectin induces the formation of procoagulant microparticles and recruits the microparticles to thrombi, anti-thrombotic strategies are currently aimed at inhibiting this interaction. Recent developments also suggest that the procoagulant potential of P-selectin could be used to treat coagulation disorders such as hemophilia A.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15059609     DOI: 10.1016/j.molmed.2004.02.007

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  29 in total

1.  Soluble P-selectin for the diagnosis of lower extremity deep venous thrombosis.

Authors:  Frank C Vandy; Cathy Stabler; Anna M Eliassen; Angela E Hawley; Kenneth E Guire; Daniel D Myers; Peter K Henke; Thomas W Wakefield
Journal:  J Vasc Surg Venous Lymphat Disord       Date:  2013-04-01

2.  Chymotrypsin-like protease (chymase) mediates endothelial activation by factors derived from preeclamptic placentas.

Authors:  J Steven Alexander; Lynn J Groome
Journal:  Reprod Sci       Date:  2009-06-03       Impact factor: 3.060

Review 3.  Haemostatic system in inflammatory bowel diseases: new players in gut inflammation.

Authors:  Franco Scaldaferri; Stefano Lancellotti; Marco Pizzoferrato; Raimondo De Cristofaro
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

4.  Effects of analgesic use on inflammation and hematology in a murine model of venous thrombosis.

Authors:  Gerald A Hish; Jose A Diaz; Angela E Hawley; Daniel D Myers; Patrick A Lester
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-09       Impact factor: 1.232

5.  Activated platelets induce Weibel-Palade-body secretion and leukocyte rolling in vivo: role of P-selectin.

Authors:  Vandana S Dole; Wolfgang Bergmeier; Heather A Mitchell; Sarah C Eichenberger; Denisa D Wagner
Journal:  Blood       Date:  2005-06-14       Impact factor: 22.113

6.  Differential regulation of endothelial exocytosis of P-selectin and von Willebrand factor by protease-activated receptors and cAMP.

Authors:  John H Cleator; Wen Qin Zhu; Douglas E Vaughan; Heidi E Hamm
Journal:  Blood       Date:  2005-12-06       Impact factor: 22.113

7.  Soluble P-selectin rescues mice from anthrax lethal toxin-induced mortality through PSGL-1 pathway-mediated correction of hemostasis.

Authors:  Der-Shan Sun; Yao-Wen Chang; Jyh-Hwa Kau; Hsin-Hsien Huang; Pei-Hsun Ho; Yin-Jeh Tzeng; Hsin-Hou Chang
Journal:  Virulence       Date:  2017-01-19       Impact factor: 5.882

8.  Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome.

Authors:  Anne-lie Ståhl; Lisa Sartz; Anders Nelsson; Zivile D Békássy; Diana Karpman
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

9.  Elevated levels of soluble P-selectin in mice alter blood-brain barrier function, exacerbate stroke, and promote atherosclerosis.

Authors:  Janka Kisucka; Anil K Chauhan; Bing-Qiao Zhao; Ian S Patten; Ayce Yesilaltay; Monty Krieger; Denisa D Wagner
Journal:  Blood       Date:  2009-04-06       Impact factor: 22.113

10.  Hemostasis and inflammation: two of a kind?

Authors:  Peter Verhamme; Marc F Hoylaerts
Journal:  Thromb J       Date:  2009-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.